125229-13-2

Upstream product

• 72922-60-2 methyl 3-amino-4-methyl-5-nitrobenzoate 
• 49592-71-4 methyl 4-methyl-3,5-dinitrobenzoate 
• 1057652-89-7 Methyl 3-fluoro-4-methyl-5-nitro-benzoate 
• 67-56-1 methanol 
• 54591-64-9 3-hydroxy-4-methyl-5-nitrobenzoic acid 
• 54591-62-7 3-amino-4-methyl-5-nitrobenzoic acid 
• 16533-71-4 3,5-dinitro-p-toluic acid 

Downstream Products

• 125229-14-3 methyl 3-methoxymethyloxy-4-methyl-5-nitrobenzene 
• 33713-02-9 3-methoxy-4-methyl-5-nitrobenzoic acid methyl ester 
• 1315454-97-7 C₂₆H₃₅NO₅Si 
• 1315454-96-6 C₂₆H₃₃NO₆Si 
• 1315454-93-3 (+/-)-methyl 3-benzoyloxy-4-(2-hydroxybut-3-ynyl)-5-nitrobenzoate 
• 1315454-94-4 (+/-)-methyl 3-benzoyloxy-4-(2-hydroxypenta-3,4-dienyl)-5-nitrobenzoate 
• 1315454-95-5 (+/-)-methyl 3-amino-5-benzyloxy-4-(2-hydroxypenta-3,4-dienyl)benzoate 
• 1315454-54-6 (+/-)-methyl 3-benzoyloxy-4-(2-hydroxypenta-3,4-dienyl)-5-nitrobenzoate 
• 704906-34-3 3-benzoyloxy-5-nitro-4-(2-oxoethyl)benzoic acid methyl ester 
• 187682-19-5 3-benzoyloxy-4-methyl-5-nitrobenzoic acid methyl ester 
• 1070887-37-4 C₁₁H₁₃NO₅ 
• 1070887-44-3 C₁₂H₁₅NO₅ 
• 125229-22-3 methyl (2S,3S)-3-[N-[1-benzenesulfonyl-4-methoxy-4-oxo-(2,3)-[N-(9-phenylfluoren-9-yl)aziridino]butyl]amino]-5-methoxymethoxy-4-methylbenzoate 
• 125229-16-5 3-Benzenesulfonylamino-5-methoxymethoxy-4-methyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

Development of a flexible strategy towards FR900482 and the mitomycins

FR900482 and the mitomycins are two intriguing classes of alkaloid natural products that have analogous biological mechanisms and obvious structural similarity. Both classes possess potent anticancer activity, a feature that has led to their investigation

Orally active zwitterionic factor Xa inhibitors with long duration of action

We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administrat

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Formal enantiospecific synthesis of (+)-FR900482

The enantiospecific synthesis of FK973, and thus a formal enantiospecific synthesis of the antitumor antibiotic (+)-FR900482, is reported. Addition of aniline 8 to chiral epoxide 9, prepared from L-vinylglycine, afforded amino alcohol 12. After protection of the aliphatic nitrogen with the 9-phenylfluoren-9-yl group, to preserve the acidic stereocenter from racemization, formation of the aziridine 14 and intramolecular condensation under basic conditions gave azocinone 15. Hydroxymethylation at the benzylic position was achieved by a process involving methylenation, epoxidation, and hydrogenolysis; the absolute stereochemistry of the resulting alcohol 23 was determined by X-ray crystallographic analysis. The hydroxyl group of 23 was carbamoylated, and the aromatic amine was deprotected electrochemically and then oxidized to give an unstable hydroxylamine that was immediately protected as acetate 26. Oxidation of 26 with DMP, followed by hydrazinolysis of the acetyl group led to spontaneous closure of the resulting N-hydroxyamino ketone to hemiketal 28, which can be considered as a fully protected precursor of FR900482 and derivatives. Acid treatment to remove the protecting groups and acetylation afforded the triacetate FK973.